Tianjin Conjustar Biotechnology Co., Ltd.

June 04, 2025 I On May 30, 2025, Conjustar Biologics announced that it’s EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for evaluating the safety and efficacy of SC-102 in patients with advanced or metastatic solid tumors expressing EphA2. Previously, SC-102 has received clinical trial approval in China and has started its clinical trial in Aug 2024, with the first patient enrolled in 2024. SC-101 has demonstrated a good safety profile in its ongoing trial. SC-101 is an innovative peptide-drug conjugate that specifically binds to tumor cells expressing EphA2, releasing a toxic payload to inhibit tumor growth. Mr. Tang Shuyi, the President of Conjustar Biologics, stated “The FDA’s approval of the IND application for SC-102 marks another new milestone in our development of innovative anti-tumor drugs. We will accelerate the clinical development of SC-102, aiming to provide more safe and effective treatment options for cancer patients worldwide.” SOURCE: Tianjin Conjustar Biotechnology